Dominari (DOMH) Competitors

Dominari (NASDAQ:DOMH) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Do institutionals & insiders hold more shares of DOMH or LXRX?

42.5% of Dominari shares are held by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. 33.0% of Dominari shares are held by company insiders. Comparatively, 4.5% of Lexicon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Is DOMH or LXRX more profitable?

Dominari has a net margin of -180.22% compared to Lexicon Pharmaceuticals' net margin of -4,109.41%. Dominari's return on equity of -32.89% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dominari	-180.22%	-32.89%	-29.47%
Lexicon Pharmaceuticals	-4,109.41%	-107.38%	-64.09%

Which has higher valuation & earnings, DOMH or LXRX?

Dominari has higher earnings, but lower revenue than Lexicon Pharmaceuticals. Dominari is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dominari	$12.59M	3.46	-$22.88M	-$3.87	-1.03
Lexicon Pharmaceuticals	$31.08M	4.04	-$177.12M	-$0.64	-0.80

Which has more volatility and risk, DOMH or LXRX?

Dominari has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, Lexicon Pharmaceuticals has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500.

Does the media favor DOMH or LXRX?

In the previous week, Dominari had 3 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 4 mentions for Dominari and 1 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 0.30 beat Dominari's score of -0.47 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dominari	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lexicon Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community believe in DOMH or LXRX?

Lexicon Pharmaceuticals received 484 more outperform votes than Dominari when rated by MarketBeat users.

Company	Underperform	Outperform
Dominari	N/A	N/A
Lexicon Pharmaceuticals	Outperform Votes 484 64.11%	Underperform Votes 271 35.89%

Do analysts recommend DOMH or LXRX?

Lexicon Pharmaceuticals has a consensus price target of $3.67, indicating a potential upside of 619.24%. Given Lexicon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Dominari.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dominari	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Lexicon Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Lexicon Pharmaceuticals beats Dominari on 11 of the 17 factors compared between the two stocks.